Ribociclib was evaluated with Binimetinib (NRAS/MEK inhibitor) [50] or Encorafenib (BRAF inhibitor) [96] in two different Phase I/II clinical trials in advanced NRAS and BRAF mutant melanoma. This evidence concerns the gene MAP2K7 and melanoma.